glp·helper
glphelper.com/semaglutide/california/palm-springs
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Palm Springs, CA

Verified Semaglutide providers in Palm Springs, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
31
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
32 of 32 shown

Find a Semaglutide provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /semaglutide/california/{city}
§ 03Getting Semaglutide in Palm Springs
32 providers · Palm Springs, CA

How to get Semaglutide in Palm Springs.

32 GLP-1 prescribers and 6 local resource types are on record for Palm Springs, plus 3 nearby towns in the directory.

Prescribers in Palm Springs
32 prescribers
32 GLP-1 prescribers in Palm Springs, most listed as Family Medicine (14), Internal Medicine (10) and Internal Medicine, Endocrinology, Diabetes & Metabolism (4). Any California-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Beaumont (24 providers), Moreno Valley (29 providers) and Perris (18 providers).
Around the prescription in Palm Springs
6 listed nearby
18 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 5 physiotherapists and 10 places to move are on record near Palm Springs.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Palm Springs

Palm Springs, California has a population of 44,575 people. The adult obesity rate in Palm Springs is an age-adjusted estimate of 35.6%, 6.5 percentage points above the California state rate of 29.1%. Diagnosed diabetes reaches 9.8% of adults in Palm Springs. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 21.8% of adults in Palm Springs.

of Palm Springs adults have obesity
35.6%
diagnosed diabetes
9.8%
no regular physical activity
21.8%

Age-adjusted estimates for Palm Springs, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossweight regain after stopping
§ 05Support around Semaglutide in Palm Springs
6 fitness clubs

The prescription is one part. Here is the rest, in Palm Springs.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Palm Springs, CA, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Steel Gym
FITNESS
4.3 on Google · 302 reviews
1751 N Sunrise Way
Website
LYV Fitness | Megaformer Training in Palm Springs
FITNESS
5.0 on Google · 124 reviews
1701 N Palm Canyon Dr #8
Website
Forja Strength | Personal Fitness Center
FITNESS
4.8 on Google · 86 reviews
3520 N Anza Rd
Website
SuperSet Gym Personal Training & Fitness Palm Springs
FITNESS
5.0 on Google · 28 reviews
888 E Research Dr Ste 108
Website
Crossfit Palm Springs
GYM
5.0 on Google · 127 reviews
1281 N Gene Autry Trail Unit B
Website
Fit in 42 Personal Training Studio Palm Springs
GYM
4.9 on Google · 89 reviews
68100 Ramon Rd Ste B3 and B4
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Edgar Alvarado, RDN
RD
Registered dietitian
275 N El Cielo Rd
Call 760-320-8814NPI 1063293421
Orville Bigelow, R.D
RD
Registered dietitian
3480 E Chia Rd
Call 760-483-3480NPI 1730508961
Jared Campbell, RD
RD
Registered dietitian
1180 N Indian Canyon Dr
Call 760-534-5954NPI 1700869005
Bonnie Chin
RD
Registered dietitian
3961 E Camino San Miguel
Call 909-735-0627NPI 1902689706
Claire Chiu, RD
RD
Registered dietitian · Pediatric
1150 N Indian Canyon Dr
Call 760-323-6272NPI 1386072502
Jessica Cruz-Castro, RDN
RD
Registered dietitian
47923 Oasis St
Call 760-863-8283NPI 1982436465
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in California

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]